iifl-logo

Pfizer Ltd Annually Results

4,949.8
(10.78%)
May 20, 2025|03:31:12 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Nov-2009Nov-2008Nov-2007Nov-2006Nov-2005

Gross Sales

772.27

681.7

676.69

770.59

702.34

Excise Duty

0

0

0

60.4

54.15

Net Sales

772.27

681.7

676.69

710.2

648.17

Other Operating Income

24.37

22.89

0

0

0

Other Income

71.05

278.01

343.07

59.59

41.06

Total Income

867.69

982.6

1,019.76

769.79

689.23

Total Expenditure

649.39

552.35

558.82

594.02

563.36

PBIDT

218.3

430.25

460.94

175.77

125.87

Interest

0

0

0.01

0.07

0.15

PBDT

218.3

430.25

460.92

175.71

125.7

Depreciation

8.28

11.11

9.57

13.06

13.85

Minority Interest Before NP

0

0

0

0

0

Tax

72.88

119.55

111.33

56.31

41.13

Deferred Tax

0

0

0

0

0

Reported Profit After Tax

137.11

299.57

340

106.33

70.73

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

137.11

299.57

340

106.33

70.73

Extra-ordinary Items

-7.13

148.6

-13.06

-15.27

-14.77

Adjusted Profit After Extra-ordinary item

144.24

150.97

353.06

121.61

85.51

EPS (Unit Curr.)

48.95

100.4

113.94

35.63

23.7

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

275

125

100

Equity

29.84

29.84

29.84

29.84

29.84

Public Shareholding (Number)

87,28,269

1,75,38,504

1,75,38,504

1,75,38,502

1,75,38,502

Public Shareholding (%)

29.25

58.77

58.77

59

59

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

2,11,13,172

0

0

0

0

Non Encumbered - % in Total Promoters Holding

100

0

0

0

0

Non Encumbered - % in Total Equity

70.75

0

0

0

0

PBIDTM(%)

28.26

63.11

68.11

24.75

19.41

PBDTM(%)

28.26

63.11

68.11

24.74

19.39

PATM(%)

17.75

43.94

50.24

14.97

10.91

Pfizer: Related NEWS

Pfizer Partners with Mylan to Boost Ativan and Pacitane Sales in India
23 Feb 2025|11:51 PM

Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.

Read More
Pfizer Ties Up with Mylan to Boost Ativan and Pacitane Sales in India
21 Feb 2025|05:31 PM

The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.

Read More
Pfizer India Q3 Profit Slips 2% YoY
31 Jan 2025|11:34 PM

Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24

Read More
Pfizer reports 61% YoY profit surge in Q1 2024
30 Jul 2024|09:44 AM

At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.